Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK's Arexvy provides protection over three RSV seasons, trial shows

(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons. Tony Wood, chief scientific officer at the pharma giant, said the company was "excited" by the data from the AReSVi-006 trial, which evaluated the efficacy of Arexvy against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older.

"This is the only RSV vaccine with efficacy and safety data available through three full seasons," Woods said in a statement on Tuesday.

The results showed that after a single dose of Arexvy, cumulative efficacy over three full RSV seasons was clinically meaningful at 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD, when compared with a placebo. In the third season, the vaccine's efficacy was 48.0% against RSV-LRTD.

"We will continue to provide data on longer term follow-up to help recommending bodies determine future revaccination schedules," Woods said.

GSK's stock, which was trading in the red in line with the market before the announcement, held on to losses despite the positive news. Share were down 1.6% at 1,456p by 1303 BST.

Share this article

Related Sharecast Articles

Thames Water creditors seek support for £1.5bn rescue fund
(Sharecast News) - A coalition of Thames Water's creditors was reported to be seeking additional investors to support a £1.5bn rescue fund on Monday, aimed at stabilising the troubled water utility and sustaining its operations through to next October.
Zahawi reportedly helping Dovid Efune in £550m Telegraph bid
(Sharecast News) - Former Conservative chancellor Nadhim Zahawi is actively engaged in efforts to support a £550m takeover of the Daily and Sunday Telegraph led by Dovid Efune, a New York-based media investor and current proprietor of the New York Sun, it was reported on Monday.
Croma Security Solutions reports solid final results
(Sharecast News) - Croma Security Solutions Group reported solid financial results for the year ended 30 June on Monday, with group revenue rising 8.9% to £8.74m, after the first full year under its new strategic direction.
Zotefoams confident in meeting full-year expectations
(Sharecast News) - Zotefoams reported a robust trading performance for the first nine months of the year on Monday, with year-to-date sales ahead 23% at £110.7m, compared to the same period last year.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.